Colospa - myotropic spasmolytic with selective effect on unstriated muscles of digestive tract. Eliminates a spasm, without influencing a normal peristaltics of intestines. Unlike cholinolytic medicine, Colospa does not affect at muscarinic receptor and does not cause characteristic of antispasmodics with muscarinic receptor action of side effects (feeling of dryness in a mouth, vision disorders, an urination delay) that allows for patients to take it at prostatauxe or glaucoma. Taking of Colospa is not followed by development of reflex hypotonia of intestines.

Zocor is indicated to reduce mortality due to coronary artery disease. It is prescribed for the reduction of risk of serious vascular and coronary complications: non-fatal myocardial infarction, coronary death, stroke; revascularization operations. Designed to reduce the risk of the need for coronary blood flow restoration; rot reduce the risk of the need for surgical intervention to restore peripheral blood flow and other types of non-coronary revascularization; to reduce the risk of hospitalization in connection with attacks of angina pectoris; to decrease in the elevated level of total cholesterol, LDL cholesterol, triglycerides. apolipoprotein B; for increasing HDL cholesterol in patients with primary hypercholesterolemia, including heterozygous familial hypercholesterolemia.